Long-term results of fluocinolone acetonide intravitreal implant in Behçet intractable posterior uveitis

Oh, Eun Kyu; Lee, Eun Kyoung; Yu, Hyeong Gon

doi:10.1016/j.jcjo.2014.03.004

Cited by 13 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following the procedure, the visual acuity of six eyes (75%) improved by three lines or more, five patients discontinued all systemic medications, and six eyes (75%) experienced a postoperative intraocular pressure peak above 30 mmHg, with five patients requiring glaucoma shunt surgery for intraocular pressure management. The results indicated that this therapy effectively controlled refractory BU, with the primary complication being elevated intraocular pressure, necessitating vigilance for potential infection [ 41 ]. In 2019, the POINT trial, a multicenter, randomized clinical study, found that both intravitreal triamcinolone acetonide (ITA) and the intravitreal dexamethasone implant (IDI) offered superior efficacy compared to periocular triamcinolone acetonide (PTA) in treating uveitic macular edema, signified by greater reductions in central subfield thickness and better visual acuity improvements, albeit with a modestly increased risk of intraocular pressure elevation.…”

Section: Topical Gcsmentioning

confidence: 99%

Optimizing glucocorticoid therapy for Behçet's uveitis: efficacy, adverse effects, and advances in combination approaches

Huang

et al. 2023

Int Ophthalmol

View full text Add to dashboard Cite

Behçet's uveitis (BU) is a debilitating manifestation of Behçet's disease, often requiring prompt and aggressive treatment to prevent vision loss. Glucocorticoids (GCS) serve as a first-line therapy for BU; however, their long-term, high-dose use can result in significant adverse effects. This review summarizes the efficacy, adverse effects, and advances in combination therapy involving GCS for the management of BU. We discuss the benefits and drawbacks of various GCS administration routes, including periocular and intravitreal injections, intravitreal sustained-release devices, and systemic therapy, highlighting the role of fluocinolone acetonide and dexamethasone as primary sustained-release formulations. Moreover, we underscore the importance of combining GCS with immunosuppressive drugs and biological agents to minimize adverse reactions and optimize therapeutic outcomes. The review concludes that, while GCS remain a crucial component of BU treatment, careful consideration of their administration and combination with other therapies is essential to achieve long-term remission and improved visual outcomes for patients with BU.

show abstract

Section: Topical Gcsmentioning

confidence: 99%